Urological applications of botulinum toxins;Toxines botuliques: Applications urologiques

Progres en Urologie

Volumn 16, Issue 3, 2006, Pages 263-274

  Karsenty, Gilles ^a,b,c   Corcos, Jacques ^b   Schurch, Brigitte ^c  

^a Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^b MCGILL UNIVERSITY   (Canada)

^c BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Benign prostatic hyperplasia; Botulinum toxin; Incontinence; Neurogenic bladder; Urinary retention

Indexed keywords

BOTULINUM TOXIN;

HUMAN; INJECTION; MICTURITION DISORDER; REVIEW;

BOTULINUM TOXINS; HUMANS; INJECTIONS; URINATION DISORDERS;

EID: 33748078132     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. LAMANNA C.: The most poisonous poison. Science, 1959; 130: 763-772.
2. JOHNSON E.A.: Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol., 1999; 53: 551-575.
3. CHERINGTON M.: Botulism: update and review. Semin. Neurol., 2004; 24: 155-163.
4. HALLEN M.: Effect of botulinum toxin at the neuromuscular junction, in Brin F, Hallet M, Jankovic J: Scientific and therapeutic aspect of botulinum toxin, Lippincott Williams and Wilkins, 1999; 167-170.
5. MACKENZIE I., BURNSTOCK G., DOLLY J.O.: The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience, 1982; 7: 997-1006.
6. WELCH M.J., PURKISS J.R., FOSTER K.A.: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon., 2000; 38: 245-258.
7. DE PAIVA A., MEUNIER F.A., MOLGO J., AOKI K.R., DOLLY J.O.: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA, 1999; 96: 3200-3205.
8. SETLER P.E.: Therapeutic use of botulinum toxins: background and history. Clin. J. Pain, 2002; 18: S119-124.
9. BROOKS V.B.: Motor nerve filament block produced by botulinum toxin. Science, 1953; 117: 334-339.
10. SCOTT A.B., ROSENBAUM A., COLLINS C.C.: Pharmacologic weakening of extraocular muscles. Invest. Ophthalmol., 1973; 12: 924-927.
11. SCOTT A.B.: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus., 1980; 17: 21-25.
12. JANKOVIC J.: Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry., 2004; 75: 951-957.
13. APOSTOLIDIS A., POPAT R., YIANGOU Y., COCKAYNE D., FORD A.P., DAVIS J.B., DASGUPTA P., FOWLER C.J., ANAND P.: Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J. Urol., 2005; 174: 977-982.
14. KHERA M., SOMOGYI G.T., KISS S., BOONE T.B., SMITH C.P.: Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem. Int., 2004; 45: 987-993.
15. SMITH C.P., RADZISZEWSKI P., BORKOWSKI A., SOMOGYI G.T., BOONE T.B., CHANCELLOR M.B.: Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004; 64: 871-875.
16. AOKI K.R.: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology, 2005; 26: 785-793.
17. DYKSTRA D.D., SIDI A.A., SCOTT A.B., PAGEL J.M., GOLDISH G.D.: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol., 1988; 139: 919-922.
18. SCHURCH B., STOHRER M., KRAMER G., SCHMID D.M., GAUL G., HAURI D.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol., 2000; 164: 692-697.
19. RAPP D.E., LUCIONI A., KATZ E.E., O'CONNOR R.C., GERBER G.S., BALES G.T.: Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology, 2004; 63: 1071-1075.
20. MARIA G., BRISINDA G., CIVELLO I.M., BENTIVOGLIO A.R., SGANGA G., ALBANESE A.: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003; 62: 259-264.
21. PHILLIPS B., BALL C., SACKETT D., BADENOCH D., STRAUS S., HAYNES B., DAWES M.: Levels of evidence and grades of recommendation., http://www.cebm.net/ levels_of_evidence.asp, Oxford centre for Evidence-based Medicine, 2001.
22. SCHURCH B., HODLER J., RODIC B.: Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J. Neurol. Neurosurg. Psychiatry, 1997; 63: 474-476.
23. SCHURCH B., HAURI D., RODIC B., CURT A., MEYER M., ROSSIER A.B.: Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J. Urol., 1996; 155: 1023-1029.
24. DE SEZE M., PETIT H., GALLIEN P., DE SEZE M.P., JOSEPH P.A., MAZAUX J.M., BARAT M.: Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol., 2002; 42: 56-62.
25. DYKSTRA D.D., SIDI A.A.: Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch. Phys. Med. Rehabil. 1990; 71: 24-26.
26. KUO H.C.: Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J. Urol., 2003; 170: 1908-1912.
27. KUO H.C.: Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology, 2003; 61: 550-554.
28. PETIT H., WIART L., GAUJARD E., LE BRETON F., FERRIERE J.M., LAGUENY A., JOSEPH P.A., BARAT M.: Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord, 1998; 36: 91-94.
29. PHELAN M.W., FRANKS M., SOMOGYI G.T., YOKOYAMA T., FRASER M.O., LAVELLE J.P., YOSHIMURA N., CHANCELLOR M.B.: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J. Urol., 2001; 165: 1107-1110
30. REITZ A., SCHURCH B.: Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J. Urol., 2004; 171: 804-805.
31. SMITH C.P., NISHIGUCHI J., O'LEARY M., YOSHIMURA N., CHANCELLOR M.B.: Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology, 2005; 65: 37-41.
32. SMITH C.P., O'LEARY M., ERICKSON J., SOMOGYI G.T., CHANCELLOR M.B.: Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int. Urogynecol. J. Pelvic Floor Dysfunct., 2002; 13: 185-186.
33. ZERMANN D., ISHIGOOKA M., SCHUBERT J., SCHMIDT R.A.: Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur. Urol., 2000; 38: 393-399.
34. FOWLER C.J., BETTS C.D., CHRISTMAS T.J., SWASH M., FOWLER C.G.: Botulinum toxin in the treatment of chronic urinary retention in women. Br. J. Urol., 1992; 70: 387-389.
35. WHEELER J.S., JR., WALTER J.S., CHINTAM R.S., RAO S.: Botulinum toxin injections for voiding dysfunction following SCI. J. Spinal Cord Med., 1998; 21: 227-229.
36. GALLIEN P., ROBINEAU S., VERIN M., LE BOT M.P., NICOLAS B., BRISSOT R.: Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch. Phys. Med. Rehabil., 1998; 79: 715-717.
37. DE LAET K., WYNDAELE J.J.: Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord., 2005; 43: 397-399.
38. KUO H.C.: Prostate botulinum A toxin injection-an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology, 2005; 65: 670-674.
39. KUO H.C.: Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology, 2005; 66: 94-98.
40. Reitz A., Stohrer M., Kramer G., Del Popolo G., Chartier-Kastler E., Pannek J., Burgdorfer H., Gocking K., Madersbacher H., Schumacher S., Richter R., von Tobel J., Schurch B.: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol., 2004; 45: 510-515.
41. BAGI P., BIERING-SORENSEN F.: Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand. J. Urol. Nephrol., 2004; 38: 495-498.
42. HAJEBRAHIMI S., ALTAWEEL W., CADORET J., COHEN E., CORCOS J.: Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can. J. Urol., 2005; 12: 2543-2546.
43. KESSLER T.M., DANUSER H., SCHUMACHER M., STUDER U.E., BURKHARD F.C.: Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol. Urodyn., 2005; 24: 231-236.
44. SCHURCH B., DE SEZE M., DENYS P., CHARTIER-KASTLER E., HAAB F., EVERAERT K., PLANTE P., PERROUIN-VERBE B., KUMAR C., FRACZEK S., BRIN M.F.: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol., 2005; 174: 196-200.
45. POPAT R., APOSTOLIDIS A., KALSI V., GONZALES G., FOWLER C.J., DASGUPTA P.: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J. Urol., 2005; 174: 984-989.
46. KUO H.C.: Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 2004; 63: 868-872.
47. GROSSE J., KRAMER G., STOHRER M.: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur. Urol., 2005; 47: 653-659.
48. PISTOLESI D., SELLI C., ROSSI B., STAMPACCHIA G.: Botulinum toxin type B for type A resistant bladder spasticity. J. Urol., 2004; 171: 802-803.
49. GIANNANTONI A., DI STASI S.M., STEPHEN R.L., BINI V., COSTANTINI E., PORENA M.: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J. Urol., 2004; 172: 240-243.
50. SCHULTE-BAUKLOH H., MICHAEL T., STURZEBECHER B., KNISPEL H.H.: Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur. Urol., 2003; 44: 139-143.
51. RICCABONA M., KOEN M., SCHINDLER M., GOEDELE B., PYCHA A., LUSUARDI L., BAUER S.B.: Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J. Urol., 2004; 171: 845-848.
52. SCHURCH B., CORCOS J.: Botulinum toxin injections for paediatric incontinence. Curr. Opin. Urol., 2005; 15: 264-267.
53. FLYNN M.K., WEBSTER G.D., AMUNDSEN C.L.: The effect of botulinum-a toxin on patients with severe urge urinary incontinence. J. Urol., 2004; 172: 2316-2320.
54. SCHULTE-BAUKLOH H., WEISS C., STOLZE T., HERHOLZ J., STURZEBECHER B., MILLER K., KNISPEL H.H.: Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur. Urol., 2005; 48: 984-990.
55. SCHULTE-BAUKLOH H., WEISS C., STOLZE T., STURZEBECHER B., KNISPEL H.H.: Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology, 2005; 66: 82-87.
56. DYKSTRA D., ENRIQUEZ A., VALLEY M.: Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int. Urogynecol. J. Pelvic Floor Dysfunct., 2003; 14: 424-426.
57. DOGGWEILER R., ZERMANN D.H., ISHIGOOKA M., SCHMIDT R.A.: Botox-induced prostatic involution. Prostate, 1998; 37: 44-50.
58. MCGUIRE E.J., WOODSIDE J.R., BORDEN T.A., WEISS R.M.: Prognostic value of urodynamic testing in myelodysplastic patients. 1981; J. Urol., 2002; 167: 1049-1053.
59. BONNIAUD V., PARRATTE B., AMARENCO G., JACKOWSKI D., DIDIER J.P., GUYATT G.: Measuring quality of life in multiple sclerosis patients with urinary disorders using the Qualiveen questionnaire. Arch. Phys. Med. Rehabil., 2004; 85: 1317-1323.
60. COSTA P., PERROUIN-VERBE B., COLVEZ A., DIDIER J., MARQUIS P., MARREL A., AMARENCO G., ESPIRAC B., LERICHE A.: Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur. Urol., 2001; 39: 107-113.
61. RUFFION A., DEMBELE D., N'GOI C., MOREL-JOURNEL N., LERICHE A.: Sacral root neuromodulation for the treatment of urinary incontinence reported to detrusor hyperactivity. Neurochirurgie, 2003; 49: 377-382.
62. ELHILALI M.M., KHALED S.M., KASHIWABARA T., ELZAYAT E., CORCOS J.: Sacral neuromodulation: long-term experience of one center. Urology, 2005; 65: 1114-1117.
63. ROVNER E., PROPERT K.J., BRENSINGER C., WEIN A.J., FOY M., KIRKEMO A., LANDIS J.R., KUSEK J.W., NYBERG L.M.: Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology, 2000; 56: 940-945.
64. NAUMANN M., JANKOVIC J.: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr. Med. Res. Opin., 2004; 20: 981-990.
65. HAFERKAMP A., SCHURCH B., REITZ A., KRENGEL U., GROSSE J., KRAMER G., SCHUMACHER S., BASTIAN P.J., BUTTNER R., MULLER S.C., STOHRER M.: Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur. Urol., 2004; 46: 784-791.
66. SCHURCH B., SCHMID D.M., STOHRER M.: Treatment of neurogenic incontinence with botulinum toxin A. N. Engl. J. Med., 2000; 342: 665.